Breast cancer remains one of the most prevalent malignancies worldwide, demanding a specialized and multidisciplinary approach to care. Breast Oncology focuses on the diagnosis, treatment, and long-term management of patients with breast malignancies, integrating advances in surgery, radiation, systemic therapies, and targeted interventions. Precision medicine has become a cornerstone of breast oncology, with molecular profiling and biomarker analysis guiding therapy selection, including hormone therapies, HER2-targeted agents, and immunotherapies. Early detection through screening programs, coupled with risk stratification and personalized treatment planning, has significantly improved survival outcomes and reduced disease recurrence. Multidisciplinary teams—including surgeons, medical oncologists, radiation oncologists, and supportive care specialists—ensure that patient-centered care addresses both clinical and psychosocial needs.
The field of Breast Oncology continues to evolve with the development of novel therapeutics, combination regimens, and clinical trial designs that aim to improve efficacy and minimize toxicity. Advances in imaging, liquid biopsy, and genomic testing allow for real-time monitoring of disease progression and therapy response, enabling adaptive treatment strategies. Survivorship care, patient education, and supportive services are integral to maintaining quality of life during and after treatment. By combining innovative science with comprehensive clinical care, breast oncology strives to provide patients with durable responses, improved long-term outcomes, and a holistic approach to cancer management that extends beyond disease control to overall well-being.
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : Nanomedicine in humans: 30 years of fighting diseases
Thomas J Webster, Northeastern University, United States
Title : Diagnosis and treatment of primary cardiac lymphoma in an immunocompetent 27-year-old man
Moataz Taha Mahmoud Abdelsalam, Madinah Cardiac Center, Saudi Arabia
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Multiplexed biosensor detection of cancer biomarkers
Michael Thompson, University of Toronto, Canada
Title : Personalized and Precision Medicine (PPM) through the view of biodesign-inspired translational research: An option for clinical oncologists, caregivers, and consumers to realize the potential of genomics-informed care to secure human biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation